Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?

The imbalance between BCL-2 homologues and pro-death counterparts frequently noted in cancer cells endows them with a cell autonomous survival advantage. To eradicate ectopic cells, inhibitors of these homologues (BH3 mimetics) were developed to trigger, during anticancer treatment, full activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Barillé-Nion, Sophie, Lohard, Steven, Juin, Philippe P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464802/
https://www.ncbi.nlm.nih.gov/pubmed/32722518
http://dx.doi.org/10.3390/biom10081109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464802/
https://www.ncbi.nlm.nih.gov/pubmed/32722518
http://dx.doi.org/10.3390/biom10081109

Ejemplares similares